Eli Lilly and Company (NYSE:LLY) Shares Up 1.9% - Here's Why

Key Points

• Eli Lilly shares rose 1.9% on Wednesday, trading as high as $1,093 and closing around $1,085, with volume below the average session level.
• The main catalyst was Lilly’s announcement that it will acquire Curevo, LimmaTech Biologics, and Vaccine Company in deals worth up to about $3.83 billion, expanding its push into infectious disease and vaccines.
• Investor sentiment remains supported by Lilly’s strong obesity-drug business and robust financial performance, with the company recently beating earnings and revenue estimates and analysts maintaining a broadly bullish outlook.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s share price shot up 1.9% during trading on Wednesday . The company traded as high as $1,093.00 and last traded at $1,085.3570. 2,535,932 shares were traded during mid-day trading, a decline of 20% from the average session volume of 3,179,649 shares. The stock had previously closed at $1,064.74.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced agreements to acquire three privately held vaccine developers — Curevo, LimmaTech Biologics, and Vaccine Company — in deals worth up to about $3.83 billion, signaling a major push into infectious disease prevention and broadening its pipeline. Lilly announces three acquisitions to build infectious disease portfolio
• Positive Sentiment: The acquisitions give Lilly exposure to vaccine targets including shingles, bacterial infections, and Epstein-Barr virus, which investors view as a sign the company is using cash flow from its obesity drugs to build new growth engines. Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
• Positive Sentiment: Analysts and market commentary have continued to highlight Lilly’s strong momentum and long-term leadership in weight-loss drugs, reinforcing confidence that the stock’s core obesity franchise remains a major earnings driver. Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
• Neutral Sentiment: Lilly also said it will participate in Goldman Sachs’ Global Healthcare Conference on June 9, an upcoming investor-relations event that may provide updates but does not change fundamentals by itself. Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
• Neutral Sentiment: Several articles noted that President Trump bought Lilly shares in Q1, but commentary emphasized that the company’s fundamentals and pipeline are the bigger driver for investors than any single insider-style purchase. President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?

Analyst Ratings Changes

A number of research firms recently commented on LLY. Wolfe Research reaffirmed an "outperform" rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Truist Financial reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Bank of America raised their price objective on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a "buy" rating in a research note on Tuesday. BMO Capital Markets reaffirmed an "outperform" rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, Leerink Partners set a $1,119.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $1,227.00.

Eli Lilly and Company Stock Performance

The firm's fifty day moving average price is $946.28 and its 200 day moving average price is $1,006.64. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $1.02 trillion, a PE ratio of 38.56, a PEG ratio of 1.16 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company's revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 24.58%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LLY. Norges Bank bought a new position in Eli Lilly and Company in the 4th quarter worth $12,976,634,000. Capital Research Global Investors raised its holdings in Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock worth $19,141,787,000 after acquiring an additional 4,332,008 shares during the period. J. Stern & Co. LLP raised its holdings in Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company's stock worth $4,047,245,000 after acquiring an additional 4,038,502 shares during the period. Cardano Risk Management B.V. raised its holdings in Eli Lilly and Company by 876.1% in the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company's stock worth $2,552,419,000 after acquiring an additional 2,131,734 shares during the period. Finally, Fifth Third Bancorp raised its holdings in Eli Lilly and Company by 321.3% in the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock worth $1,805,959,000 after acquiring an additional 1,497,423 shares during the period. Institutional investors own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.